Cisen Pharmaceutical Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation paliperidone extended-release tablets (specification: 3 mg, produced by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation paliperidone extended-release tablets (Rida, specification: 3 mg, produced by Janssen Cilag Manufacturing L.L.C.) in healthy subjects after a single oral administration under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting and fed conditions. Secondary purpose of the study is to evaluate the safety of the test preparation paliperidone extended-release tablets (specification: 3 mg) and the reference preparation paliperidone extended-release tablets (Rida, specification: 3 mg) in healthy subjects.

Primary objective: To evaluate the effectiveness of lifalast eye drops in the treatment of patients with dry eye. Secondary objective: To evaluate the safety of lifalast eye drops.

The main purpose of the study is to study the pharmacokinetics of the test preparation Moxifloxacin Hydrochloride Tablets (Specification: 0.4 g, produced by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox, Specification: 0.4 g, certified by Bayer Vital GmbH) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation Moxifloxacin Hydrochloride Tablets (Specification: 0.4 g) and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox, Specification: 0.4 g) in healthy subjects.